Compare · ENVX vs TMO
ENVX vs TMO
Side-by-side comparison of Enovix Corporation (ENVX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- ENVX operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.52B, about 109.3x ENVX ($1.60B).
- Over the past year, ENVX is down 14.8% and TMO is up 14.9% - TMO leads by 29.7 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 10 for ENVX).
- TMO has more recent analyst coverage (25 ratings vs 24 for ENVX).
- Company
- Enovix Corporation
- Thermo Fisher Scientific Inc
- Price
- $7.32+0.76%
- $469.56-0.67%
- Market cap
- $1.60B
- $174.52B
- 1M return
- +14.20%
- -1.03%
- 1Y return
- -14.78%
- +14.92%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 10
- 17
- Recent ratings
- 24
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest ENVX
- SEC Form DEFA14A filed by Enovix Corporation
- SEC Form DEFA14A filed by Enovix Corporation
- Chief Legal Officer Chakravarthy Arthi was granted 6,756 shares and covered exercise/tax liability with 3,578 shares, increasing direct ownership by 0.53% to 604,512 units (SEC Form 4) (for withholding tax)
- Chief Accounting Officer Truong Kristina was granted 5,718 shares and covered exercise/tax liability with 3,028 shares, increasing direct ownership by 0.86% to 315,622 units (SEC Form 4) to cover taxes
- Chief Financial Officer Benton Ryan A was granted 5,103 shares and covered exercise/tax liability with 2,703 shares, increasing direct ownership by 0.26% to 925,368 units (SEC Form 4) to satisfy withholding tax
- President and CEO Talluri Rajendra K was granted 17,794 shares and covered exercise/tax liability with 9,422 shares, increasing direct ownership by 0.27% to 3,066,567 units (SEC Form 4) (tax liability)
- SEC Form DEFA14A filed by Enovix Corporation
- Chief Legal Officer Chakravarthy Arthi covered exercise/tax liability with 2,221 shares, decreasing direct ownership by 0.37% to 601,334 units (SEC Form 4) (tax withholding)
- President and CEO Talluri Rajendra K covered exercise/tax liability with 17,650 shares, decreasing direct ownership by 0.57% to 3,058,195 units (SEC Form 4) to satisfy withholding obligation
- Enovix Announces May and June Investor Events
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)